Clinical Trials

Showing trials with last updates posted in 2024.

NCT04659044 | TERMINATED | PHASE2
3 participants

Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

Study Type:
INTERVENTIONAL
Last Updated:
2024-09-19
Start Date:
2021-04-01
Completion:
2024-03-28
Conditions
  • Recurrent B-Cell Non-Hodgkin Lymphoma
  • Recurrent Grade 1 Follicular Lymphoma
  • Recurrent Grade 2 Follicular Lymphoma
  • Recurrent Grade 3a Follicular Lymphoma
  • Recurrent Mantle Cell Lymphoma
  • Recurrent Marginal Zone Lymphoma
  • Recurrent Small Lymphocytic Lymphoma
  • Refractory B-Cell Non-Hodgkin Lymphoma
  • Refractory Grade 1 Follicular Lymphoma
  • Refractory Grade 2 Follicular Lymphoma
  • Refractory Grade 3a Follicular Lymphoma
  • Refractory Mantle Cell Lymphoma
  • Refractory Marginal Zone Lymphoma
  • Refractory Small Lymphocytic Lymphoma
Interventions
  • DRUG
  • BIOLOGICAL
NCT04609943 | TERMINATED | PHASE1
16 participants
NCT04580238 | WITHDRAWN | PHASE1
0 participants

Onabotulinum Toxin A (Botox) for the Treatment of Persistent Post-Stroke and Vascular Headache

Study Type:
INTERVENTIONAL
Last Updated:
2024-09-19
Start Date:
2023-12-31
Completion:
2025-01-31
Conditions
  • Stroke (CVA) or TIA
  • Headache, Migraine
  • Botulinum Toxins, Type A
  • Cerebral Venous Sinus Thrombosis
  • Carotid Dissection Artery
  • Vertebral Dissection Artery
  • Hemorrhagic Stroke
  • Reversible Cerebral Vasoconstriction Syndrome
Interventions
  • DRUG
  • COMBINATION_PRODUCT
No Results Yet
Previous
Sorted by latest updates
Next
Showing 40 trials per page